{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:44:49Z","timestamp":1792147489720,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"DOI":"10.1038\/s41581-026-01136-3","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:48Z","timestamp":1792144188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome"],"prefix":"10.1038","author":[{"given":"Magdalena","family":"Madero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-026-01109-6","author":"J Rangaswami","year":"2026","unstructured":"Rangaswami, J., Lo, K. B. & Ndumele, C. E. The therapeutic approach to cardiovascular\u2013kidney\u2013metabolic syndrome. Nat. Rev. Nephrol. https:\/\/doi.org\/10.1038\/s41581-026-01109-6 (2026).","journal-title":"Nat. Rev. Nephrol."},{"key":"1136_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","volume":"84","author":"J-I Shin","year":"2024","unstructured":"Shin, J.-I. et al. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. J. Am. Coll. Cardiol. 84, 683\u2013693 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1136_CR3","doi-asserted-by":"publisher","unstructured":"Kovesdy, C. P. et al. Real-world SGLT2 inhibitor (SGLT2i) use in patients with CKD in the United States [abstract]. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.202592d27ygq (2025).","DOI":"10.1681\/ASN.202592d27ygq"},{"key":"1136_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.046837","volume":"15","author":"Y Jelwan","year":"2026","unstructured":"Jelwan, Y. et al. Finerenone prescriptions in the United States (2021\u20132024) by physician specialty: analysis of use and potential in the cardiovascular-kidney-metabolic space. J. Am. Heart Assoc. 15, e046837 (2026).","journal-title":"J. Am. Heart Assoc."},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan, S. S. et al. Development and validation of the American Heart Association\u2019s PREVENT equations. Circulation 149, 430\u2013449 (2024).","journal-title":"Circulation"},{"key":"1136_CR6","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1136_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2023.2854","volume":"329","author":"NJ Pagidipati","year":"2023","unstructured":"Pagidipati, N. J. et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA 329, 1261\u20131270 (2023).","journal-title":"JAMA"},{"key":"1136_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cardfail.2023.03.012","volume":"29","author":"J Zheng","year":"2023","unstructured":"Zheng, J., Mednick, T., Heidenreich, P. A. & Sandhu, A. T. Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis. J. Card. Fail. 29, 1000\u20131013 (2023).","journal-title":"J. Card. Fail."},{"key":"1136_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly, L. A. et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2, e214182 (2021).","journal-title":"JAMA Health Forum"},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"GBD 2023 Chronic Kidney Disease Collaborators","year":"2025","unstructured":"GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461\u20132482 (2025).","journal-title":"Lancet"},{"key":"1136_CR11","first-page":"100625","volume":"28","author":"DS L\u00f3pez","year":"2023","unstructured":"L\u00f3pez, D. S., Hern\u00e1ndez Vargas, J. A., Urina-Jassir, M., Urina-Triana, M. & Franco, O. H. Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing? Lancet Reg. Health Am. 28, 100625 (2023).","journal-title":"Lancet Reg. Health Am."},{"key":"1136_CR12","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.3390\/healthcare12030382","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello, A. K. et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob. Health 12, e382\u2013e395 (2024).","journal-title":"Health"},{"key":"1136_CR13","unstructured":"World Health Organization. The Selection and Use of Essential Medicines 2021: Report of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines (WHO Technical Report Series No. 1035) (WHO, 2021)."},{"key":"1136_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","volume":"9","author":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","year":"2021","unstructured":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 9, 825\u2013836 (2021).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01136-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:49Z","timestamp":1792144189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":14,"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01136-3","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"16 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. has consulted for AstraZeneca, Bayer, and Boehringer Ingelheim, provided expert testimonies for AstraZeneca, Bayer, and Boehringer Ingelheim and received grant funding or has pending grants from AstraZeneca, Bayer, Boehringer and the Renal Research Institute. She has also received travel support from AstraZeneca.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}